SU-6668 (TSU-68) is an ATP-competitive, oxindole-based inhibitor of Flk-1/KDR, PDGFRb, and FGFR1 phosphorylation with Ki values of 2.1, 0.008, and 1.2 uM, respectively. [1] At these inhibitory levels, it was shown that SU-6668 induces antiangiogenic and proapoptotic effects in vivo. [2, 3]. Oral administration of SU6668 induced tumor regression in A431, PC-3, NCI-HT29, and Colo205 cell lines, and tumor stasis in SF767T glioma and NCI-H460 cell lines. [2]

In human myeloid leukemia cell lines and acute myeloid leukemia blasts, SU6668 was shown to inhibit the stem cell factor-induced phosphorylation of c-kit and ERK1/2 and induced apoptosis. [4]

SU-6668 (TSU-68) is an ATP-competitive, oxindole-based inhibitor of Flk-1/KDR, PDGFRb, and FGFR1 phosphorylation with Ki values of 2.1, 0.008, and 1.2 uM, respectively. [1] At these inhibitory levels, it was shown that SU-6668 induces antiangiogenic and proapoptotic effects in vivo. [2, 3]. Oral administration of SU6668 induced tumor regression in A431, PC-3, NCI-HT29, and Colo205 cell lines, and tumor stasis in SF767T glioma and NCI-H460 cell lines. [2]

In human myeloid leukemia cell lines and acute myeloid leukemia blasts, SU6668 was shown to inhibit the stem cell factor-induced phosphorylation of c-kit and ERK1/2 and induced apoptosis. [4]